In vitro Toxicology

end points or to clarify toxicity mechanisms, our in vitro assays contribute to more accurately capturing the safety profile of your test compound, while reducing the use of laboratory animals. Our in vitro toxicity assay portfolio includes assays for GLP regulatory requirements or non-GLP testing, such as screening assays. The latter allow high-throughput in vitro toxicity testing, while using only a minimal amount of substance. All assay designs can be tailored to your needs.

Our In Vitro Toxicology Portfolio:

Genotoxicity (According to ICH S2 Guidelines):

Bacterial reverse-mutation test (Ames assay)

Skin Toxicity:

  • In vitro skin irritation: Reconstructed human epidermis (RhE) test method
  • In vitro skin corrosion: RhE test method
  • In vitro 3T3 NRU phototoxicity test, according to ICH S10
  • Skin sensitization assays covering the skin sensitization AOP:
    • In chemico skin sensitization: Assays addressing the adverse outcome pathway key event on covalent binding to proteins—the direct peptide reactivity assay (DPRA)
    • In vitro skin sensitization: ARE-Nrf2 luciferase test method
    • In vitro skin sensitization assays addressing the key event on activation of dendritic cells on the adverse outcome pathway for skin sensitization

Cardiac Safety (According to ICH S7SB Guidelines):

  • Ion channel screenings (hERG, NaV1.5, CaV1.2) using automated patch clamp robots
  • Manual ion channel (hERG, NaV1.5, CaV1.2) screenings at normal or elevated temperature

Service Assets

  • Automated flow cytometry
  • High-throughput pipetting robots
  • Camera-based Ames assay unit
  • Comet imaging station
  • Fast screening assay variants that require only a minimal amount of substance, for the above-mentioned in vitro tests
  • QSAR analyses for a first toxicity screening
  • Tailor-made in vitro toxicity assay development and validation
  • Expert consultancy services on study design and compound de-risking